Category

Industry News

Home / Industry News

U.S. FDA Approves Athena Bioscience’s New Drug Application (NDA) for QDOLO™ (tramadol hydrochloride) Oral Solution

Athena Bioscience, LLC, a specialty pharmaceutical company, announced today that the U.S. Food and Drug Administration (FDA) has approved QDOLO™ (tramadol hydrochloride) Oral Solution 5mg/1mL C-IV, an opioid agonist indicated in adults for the management of pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate. Full story.

FDA Approves XARACOLL® (bupivacaine HCl) Implant, a Non-opioid, Drug-device Treatment Option for Acute Postsurgical Pain Relief for up to 24 Hours Following Open Inguinal Hernia Repair in Adults

XARACOLL is a unique, non-injectable drug-device combination in the form of a fully bioresorbable collagen implant containing bupivacaine hydrochloride. XARACOLL is placed directly into the surgical site during surgery and, after placement, releases bupivacaine immediately and over time. Full story.

FDA Approves Digital Health App for Chronic Pain Management

A new digital health tool has been approved by the U.S. Food and Drug Administration. The approval of the iOS-compatible application will enable individuals with chronic pain and movement disorders to receive personalized therapy through their mobile device. Abbott can now move forward with the Patient Controller app on compatible personal Apple smartphone devices and eliminate the need to carry a separate patient programmer device to streamline the therapeutic experience and seamlessly integrate therapy management. Full story.

AAPM Welcomes Helixmith as its Newest Corporate Relations Council Member

The AAPM Corporate Relations Council allows the Academy to partner with companies seeking new advances in the specialty of pain management and optimum quality of life for pain patients. AAPM is pleased to welcome Helixmith to its Corporate Relations Council at the Corporate Elite Associate Level.

Founded in 1996, Helixmith has been dedicated to research in gene therapy for over 20 years. Ever since it started from the founder’s lab, Helixmith has consistently worked with a purpose of identifying new approaches to develop innovative gene therapy and treat diseases with high unmet needs to help patients live longer and better lives. With their expertise in crafting genes, the company is charting new courses to explore a future of change.

Participation in the AAPM Corporate Relations Council is available to organizations that support the mission and vision of AAPM.

Learn more about the AAPM Corporate Relations Council and browse member profiles.

First Scientific Study Using Virtual Reality to Treat Chronic Pain at Home Finds AppliedVR Platform Feasible, Scalable and Effective

AppliedVR, announced results from the first randomized controlled trial (RCT), evaluating virtual-reality-based (VR) therapy for self-management of chronic pain at home. The study, which was published in JMIR-FR, found that a self-administered, skills-based VR treatment program was not only a feasible and scalable way to treat chronic pain, it also was effective at improving on multiple chronic pain outcomes. Full story

1 2 3
Privacy Settings
We use cookies to enhance your experience while using our website. If you are using our Services via a browser you can restrict, block or remove cookies through your web browser settings. We also use content and scripts from third parties that may use tracking technologies. You can selectively provide your consent below to allow such third party embeds. For complete information about the cookies we use, data we collect and how we process them, please check our Privacy Policy
Youtube
Consent to display content from Youtube
Vimeo
Consent to display content from Vimeo
Google Maps
Consent to display content from Google
Spotify
Consent to display content from Spotify
Sound Cloud
Consent to display content from Sound